Compare Stocks

→ The Gold Grab of the Century (From Colonial Metals) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LXRX Lexicon Pharmaceuticals	$1.54 -3.8%	$2.24	$0.92 ▼ $3.79	$379.21M	1.27	4.38 million shs	1.69 million shs
MNK Mallinckrodt	$0.12	$0.34	$0.75 ▼ $6.42	$1.58M	N/A	2.62 million shs	39,227 shs
OPTN OptiNose	$0.91 -2.2%	$1.47	$0.86 ▼ $2.10	$101.95M	-0.24	832,803 shs	23.36 million shs
SBBP Strongbridge Biopharma	$2.00	$2.09	$1.85 ▼ $4.26	$135.66M	1.58	866,464 shs	684,684 shs
XOMA XOMA	$25.36 -1.1%	$24.80	$13.48 ▼ $27.00	$295.19M	0.58	20,852 shs	6,778 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LXRX Lexicon Pharmaceuticals	-0.62%	-1.23%	-24.53%	-10.11%	-32.20%
MNK Mallinckrodt	0.00%	0.00%	0.00%	0.00%	-97.99%
OPTN OptiNose	-4.38%	-9.28%	-38.31%	-36.62%	-47.72%
SBBP Strongbridge Biopharma	0.00%	0.00%	0.00%	0.00%	0.00%
XOMA XOMA	-1.72%	+5.73%	+6.83%	+24.41%	+41.03%

$25,000 into $109,616 in two months? (Ad)

Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…

Go here to watch the most recent trading workshop video at no charge.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
LXRX Lexicon Pharmaceuticals	1.6115 of 5 stars	3.0	3.0	0.0	0.0	1.7	1.7	0.6
MNK Mallinckrodt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OPTN OptiNose	3.6315 of 5 stars	3.5	2.0	0.0	4.2	0.0	2.5	0.6
SBBP Strongbridge Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
XOMA XOMA	3.4897 of 5 stars	3.5	1.0	0.0	3.0	2.3	1.7	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LXRX Lexicon Pharmaceuticals	2.00	Hold	$5.00	224.68% Upside
MNK Mallinckrodt	N/A	N/A	N/A	N/A
OPTN OptiNose	3.00	Buy	$4.00	341.99% Upside
SBBP Strongbridge Biopharma	N/A	N/A	N/A	N/A
XOMA XOMA	3.00	Buy	$74.00	191.80% Upside

Current Analyst Ratings

Latest SBBP, OPTN, LXRX, XOMA, and MNK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/25/2024	XOMA XOMA	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$74.00
4/23/2024	LXRX Lexicon Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold
4/11/2024	LXRX Lexicon Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold
3/18/2024	OPTN OptiNose	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
3/18/2024	OPTN OptiNose	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$3.00 ➝ $4.00
3/11/2024	OPTN OptiNose	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$5.00
2/16/2024	XOMA XOMA	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$74.00

(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LXRX Lexicon Pharmaceuticals	$1.20M	316.01	N/A	N/A	$0.38 per share	4.05
MNK Mallinckrodt	N/A	N/A	N/A	N/A	$47.48 per share	N/A
OPTN OptiNose	$70.99M	1.44	N/A	N/A	($0.77) per share	-1.18
SBBP Strongbridge Biopharma	$30.73M	4.41	N/A	N/A	$0.98 per share	2.04
XOMA XOMA	$4.76M	62.01	N/A	N/A	$7.72 per share	3.28

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LXRX Lexicon Pharmaceuticals	-$177.12M	-$0.80	N/A	N/A	N/A	-14,573.20%	-138.54%	-71.29%	5/7/2024 (Estimated)
MNK Mallinckrodt	N/A	-$116.19	N/A	∞	N/A	-82.59%	20.32%	2.49%	N/A
OPTN OptiNose	-$35.48M	-$0.32	N/A	N/A	N/A	-50.06%	N/A	-33.05%	5/9/2024 (Estimated)
SBBP Strongbridge Biopharma	-$45.08M	-$0.78	N/A	N/A	N/A	-115.67%	-66.82%	-36.21%	N/A
XOMA XOMA	-$40.83M	-$4.04	N/A	N/A	N/A	-886.91%	-25.17%	-17.08%	5/14/2024 (Estimated)

Latest SBBP, OPTN, LXRX, XOMA, and MNK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/11/2024	Q4 2023	LXRX Lexicon Pharmaceuticals	-$0.23	-$0.20	+$0.03	-$0.20	$0.68 million	$0.70 million
3/8/2024	Q4 2023	XOMA XOMA	-$0.36	-$0.49	-$0.13	$0.89	$1.01 million	$1.83 million
3/7/2024	12/31/2023	OPTN OptiNose	-$0.10	-$0.09	+$0.01	-$0.09	$19.90 million	$19.87 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
LXRX Lexicon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MNK Mallinckrodt	N/A	N/A	N/A	N/A	N/A
OPTN OptiNose	N/A	N/A	N/A	N/A	N/A
SBBP Strongbridge Biopharma	N/A	N/A	N/A	N/A	N/A
XOMA XOMA	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LXRX Lexicon Pharmaceuticals	1.07	5.60	5.58
MNK Mallinckrodt	1.18	0.57	0.31
OPTN OptiNose	N/A	0.60	0.55
SBBP Strongbridge Biopharma	0.38	3.00	2.95
XOMA XOMA	1.34	8.68	8.68

Ownership

Institutional Ownership

Company	Institutional Ownership
LXRX Lexicon Pharmaceuticals	74.70%
MNK Mallinckrodt	83.74%
OPTN OptiNose	85.60%
SBBP Strongbridge Biopharma	52.03%
XOMA XOMA	95.92%

Insider Ownership

Company	Insider Ownership
LXRX Lexicon Pharmaceuticals	6.80%
MNK Mallinckrodt	0.30%
OPTN OptiNose	2.20%
SBBP Strongbridge Biopharma	5.10%
XOMA XOMA	7.20%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
LXRX Lexicon Pharmaceuticals	285	246.24 million	229.49 million	Optionable
MNK Mallinckrodt	2,700	13.17 million	13.13 million	Not Optionable
OPTN OptiNose	132	112.65 million	110.17 million	Not Optionable
SBBP Strongbridge Biopharma	72	67.83 million	N/A	Optionable
XOMA XOMA	13	11.64 million	10.80 million	Optionable

SBBP, OPTN, LXRX, XOMA, and MNK Headlines

Source	Headline
$XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)$	XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) finance.yahoo.com - April 25 at 8:40 AM
	XOMA's (XOMA) Buy Rating Reiterated at HC Wainwright marketbeat.com - April 25 at 8:09 AM
$XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day Ones OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)$	XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) globenewswire.com - April 25 at 7:30 AM
	XOMA (NASDAQ:XOMA) Share Price Crosses Above 200-Day Moving Average of $20.30 americanbankingnews.com - April 25 at 3:14 AM
	Actym Therapeutics Appoints Thomas Smart as CEO prnewswire.com - April 24 at 9:00 AM
	XOMA (NASDAQ:XOMA) shareholders have earned a 16% CAGR over the last five years finance.yahoo.com - April 20 at 9:43 AM
	XOMA (NASDAQ:XOMA) Share Price Passes Above Two Hundred Day Moving Average of $19.93 americanbankingnews.com - April 17 at 2:58 AM
	XOMA Co. (NASDAQ:XOMA) Shares Sold by Stonepine Capital Management LLC marketbeat.com - April 9 at 9:43 PM
	XOMA Corporation Announces Closing of Tender Offer globenewswire.com - April 3 at 9:00 AM
	XOMA Declares Quarterly Preferred Stock Dividends globenewswire.com - March 21 at 7:30 AM
	XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc. globenewswire.com - March 19 at 4:05 PM
	KINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE businesswire.com - March 13 at 11:49 AM
	XOMA Stock Earnings: XOMA Misses EPS, Misses Revenue for Q4 2023 investorplace.com - March 8 at 1:03 PM
	XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value finance.yahoo.com - March 8 at 7:51 AM
	XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value globenewswire.com - March 8 at 7:30 AM
	XOMA to Present at Upcoming Investor Conferences in March globenewswire.com - February 28 at 7:30 AM
	KINNATE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE businesswire.com - February 19 at 11:03 AM
	Compare with Maple Leaf Green World Inc (4HV0) msn.com - February 18 at 12:30 PM
	XOMA to acquire Kinnate Biopharma thepharmaletter.com - February 17 at 10:21 AM
	XOMA Mar 2024 20.000 put finance.yahoo.com - February 17 at 10:21 AM
	XOMA Jun 2024 25.000 call finance.yahoo.com - February 17 at 10:21 AM
	Biotech Royalty Aggregator XOMA To Acquire Small Cancer-Drug Developer Kinnate Biopharma benzinga.com - February 16 at 1:37 PM
	XOMA Agrees to Acquire Kinnate Biopharma marketwatch.com - February 16 at 8:36 AM
	XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right finance.yahoo.com - February 16 at 8:36 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Lexicon Pharmaceuticals

NASDAQ:LXRX

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Mallinckrodt

NYSE:MNK

Mallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines. The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.

OptiNose

NASDAQ:OPTN

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.

Strongbridge Biopharma

NASDAQ:SBBP

Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded in 1996 and is headquartered in Trevose, PA.

XOMA

NASDAQ:XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial